SILO PHARMA, INC. Proceeds from Sale of Notes Receivable
SILO PHARMA, INC. (SILO) reported Proceeds from Sale of Notes Receivable of $60.00 thousand for the 1-month period ending 2021-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfNotesReceivable · last filed 2024-08-13
- 2021-09-30: Proceeds from Sale of Notes Receivable $60.00K; Proceeds from Sale of Notes Receivable 1 month $60.00K.
| Period end | Proceeds from Sale of Notes Receivable | Proceeds from Sale of Notes Receivable 1 month |
|---|---|---|
| 2021-09-30 | $60.00K 10-Q · filed 2024-08-13 | $60.00K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |